ROSELAND, NJ, May 23, 2022 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS)a leading developer of computerized drug delivery devices that enable painless and precise injections, today announced the appointment of Ms. Benedetta Casamento to the Company’s Board of Directors.
Ms. Casamento is currently a consultant specializing in retail, finance, business operations, financial planning and analysis. Ms. Casamento previously served as Chairman of the Board and President of Allyke, Inc., an artificial intelligence company creating digital imagery insights for retail and other industries. She has also served as CEO of Calypso St. Barth, a luxury lifestyle brand, as well as a consultant to private equity firms with retail and fashion holdings. Earlier in her career, she served as Executive Vice President of Finance and Operations at The Talbots Inc. and held various leadership positions at Liz Claiborne, Inc., including President of Liz Claiborne Brands and President of Ellen Tracy Brands and Dana Buchman. She sits on the board of directors of Charles & Colvard, a world-renowned fine jewelry company. She is also involved in various charities, including serving on the board of directors of Women in Need, Inc., a non-profit organization that provides housing, programs, and other services to homeless mothers in New York City. and to their children.
Leslie Bernhard, Chairman of the Board of Milestone Scientific Inc., said, “I am delighted to welcome Benedetta to the Milestone Board of Directors. She brings an impressive background in brand marketing, business operations and finance which we believe will help support our continued growth. In particular, we look forward to his insights and input as we continually refine branding and sales strategies around our current instruments, as well as new products in our pipeline.
Ms. Casamento said, “I am honored to join Milestone at this exciting time in the company’s evolution. Milestone CompuFlo® Epidural and CathCheck™ The verification system fills an unmet need in the market, given the safety issues associated with the traditional epidural procedure. The importance of this message cannot be underestimated, both for women in labor and delivery, as well as for the millions of others who receive epidural procedures each year. In addition, I look forward to supporting the launch of new products based on Milestone’s technology platform, which offers safety and cost benefits across a wide range of potential indications.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology-driven medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise and efficient and to increase patient comfort and safety. Their exclusive DPS dynamic pressure sensing technology® instruments is the platform to advance the development of next-generation devices, regulating flow and monitoring pressure from the needle tip, through subcutaneous drug delivery platform extensions , including local anesthetic. To learn more, watch the MLSS brand video or visit Milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments regarding future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict with precision and many of which go beyond Milestone Control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve anticipated revenue growth, changes in our operating expenses, decisions adverse patent, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and risk factors detailed from time to time in Milestone’s periodic filings with of the Securities and Exchange Commission, including, without limitation, Milestone’s Annual Report for the fiscal year ended December 31, 2021. The forward-looking statements contained in this press release are based on management’s reasonable belief in the date hereof. Milestone undertakes no obligation to publicly revise or update any forward-looking statements for any reason.
David Waldman or Natalia Rudman
Crescendo Communications, LLC